Redeuced hypnotic effect with phenytoin,carbamazepine Increased drowsiness and incordination with TCAs Increased CNS depresantwith alcohol and other CNS depressants Decreased ziplocone conc. with CYP3A4 inhibitors eg erythromycin, clarithromycin, ketoconazole, itraconazole, ritronavir

Short term management of insomnia

Metallic taste or bitter after-taste, Irritability, confusion and depressed mood, aggresiveness. Incordination, anterograde, amnesia, Mild increase in LFTs , Drowsiness,lethargy and ataxia,nausea and vomitting. Rarely urticaria and various rashes.

Myastenia gravis, Respiratory failure Severe sleep apnoea syndrome, severe hepatic imparment Pregnancy, lactation, Neonates and children.

Special precautions: Hepatic and renal insufficiency. elderly Psychiatric disorders, history of drug abuse, May impair ability to drive or operate machinery Limit treatment to < 4 weeks to minimise risk of dependence Avoid abrupt discontinuation of therapy

Date of Approval        1996

Indication

Short term management of insomnia

Dosage-

Adult- 7.5mg at bed time

Elderly - initially 3.75mg at bed time

Absorption may be reduced.

Contraindicated for use during pregnancy and lactation Use with caution if required to administered